Sage nix­es pro­gram for Parkin­son’s dis­ease af­ter Phase 2 fail­ure

Sage Ther­a­peu­tics is ter­mi­nat­ing the de­vel­op­ment of its drug dalzanem­dor in Parkin­son’s dis­ease af­ter a mid-stage test end­ed in dis­ap­point­ment.

The Phase 2 PRECE­DENT tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER